Sierra is currently recruiting for its pivotal Phase 3 clinical study, MOMENTUM, a randomized
double-blind trial for myelofibrosis patients who are symptomatic and anemic, and who have been treated previously with a JAK inhibitor.
Sierra is currently recruiting for its pivotal Phase 3 clinical study, MOMENTUM, a randomized double-blind trial for myelofibrosis patients who are symptomatic and anemic, and who have been treated previously with a JAK inhibitor.